Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma
- PMID: 29200325
- PMCID: PMC7185719
- DOI: 10.1080/08880018.2017.1396386
Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma
Abstract
High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk. Given the high intensity of induction chemotherapy, neutropenic fever and infectious complications are common; however, the actual incidence is difficult to determine from clinical trial reports. We performed a retrospective review of infection-related complications in 76 children treated for high-risk neuroblastoma at Texas Children's Hospital. Medical records were reviewed for demographics, febrile neutropenia (FN) episodes, presence, and type of bacterial and fungal infections, and potential risk factors for infection. Fifty-seven percent of patients developed one or more serious bacterial or fungal infections during induction chemotherapy. Additionally, over 75% of patients had at least one admission for FN. Risk factors for developing any infection included female sex, MYCN amplification, and having Medicaid. Patients with external central venous catheters and those requiring parenteral nutrition had higher rates of bacteremia or fungemia. Each cycle, 50% were readmitted for either FN or infection. The overall burden of infectious complications was high, with 70% having two or more unplanned admissions for infection or FN. The incidence of febrile neutropenia and serious bacterial and fungal infections during induction chemotherapy for high-risk neuroblastoma is high. Most patients had at least two additional hospitalizations for infectious complications. Risk factors including female sex, MYCN amplification, payer status, and type of central access were associated with higher rates of infection in this cohort.
Abbreviations: CLABSI Central line associated blood stream infection; CTCAE Common Terminology Criteria for Adverse Events; FN Febrile neutropenia; ANC Absolute neutrophil count; TPN Total parenteral nutrition.
Keywords: Bacterial; chemotherapy; febrile neutropenia; fungal; infection; neuroblastoma.
Conflict of interest statement
Figures



Similar articles
-
A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.J Pediatr Hematol Oncol. 2006 Oct;28(10):665-70. doi: 10.1097/01.mph.0000212996.94929.0b. J Pediatr Hematol Oncol. 2006. PMID: 17023827
-
Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.Eur J Pediatr. 2024 Jan;183(1):185-202. doi: 10.1007/s00431-023-05273-w. Epub 2023 Oct 19. Eur J Pediatr. 2024. PMID: 37855927
-
Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia.Biomedica. 2013 Jan-Mar;33(1):70-7. doi: 10.1590/S0120-41572013000100009. Biomedica. 2013. PMID: 23715309
-
[Prevention and treatment of febrile neutropenia].Tumori. 1997;83(2 Suppl):S15-9. Tumori. 1997. PMID: 9235724 Review. Italian.
-
The current spectrum of infection in cancer patients with chemotherapy related neutropenia.Infection. 2014 Feb;42(1):5-13. doi: 10.1007/s15010-013-0525-9. Epub 2013 Aug 23. Infection. 2014. PMID: 23975584 Review.
Cited by
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.Pediatr Blood Cancer. 2020 Oct;67(10):e28417. doi: 10.1002/pbc.28417. Epub 2020 Jul 30. Pediatr Blood Cancer. 2020. PMID: 32729196 Free PMC article. Clinical Trial.
-
Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta Pharm Sin B. 2024 Jul;14(7):2901-2926. doi: 10.1016/j.apsb.2024.03.006. Epub 2024 Mar 11. Acta Pharm Sin B. 2024. PMID: 39027258 Free PMC article. Review.
-
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.Cancer. 2022 Jan 15;128(2):317-325. doi: 10.1002/cncr.33917. Epub 2021 Oct 8. Cancer. 2022. PMID: 34623638 Free PMC article. Clinical Trial.
-
Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2).Med Oncol. 2020 Aug 3;37(9):78. doi: 10.1007/s12032-020-01401-w. Med Oncol. 2020. PMID: 32748212 Free PMC article.
-
Microbiological Profile of Blood Stream Infections in Febrile Neutropenic Patients at a Tertiary Care Teaching Hospital in Rishikesh, Uttarakhand.J Lab Physicians. 2020 Aug;12(2):147-153. doi: 10.1055/s-0040-1716661. Epub 2020 Sep 2. J Lab Physicians. 2020. PMID: 32905287 Free PMC article.
References
-
- Howlader N, Noone AM, Krapcho M, Neyman… N. SEER cancer statistics review, 1975–2009 (vintage 2009 populations), National Cancer Institute; Bethesda, MD: 2012
-
- Rogers AE, Eisenman KM, Dolan SA et al. Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report. Pediatr Blood Cancer 2017;64 (3 - PubMed
-
- Shafey A, Ethier MC, Traubici J, Naqvi A, Sung L. Incidence, risk factors, and outcomes of enteritis, typhlitis, and colitis in children with acute leukemia. J Pediatr Hematol Oncol 2013;35 (7):514–517. - PubMed
-
- Sung L, Aplenc R, Zaoutis T, Groll AH, Gibson B, Lehrnbecher T. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer 2008;51 (4):458–460. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous